On April 15, the People's Government of Beijing Municipality held a press conference to unveil the newly released Implementation Plan for High-Quality Development of BioPark (hereinafter referred to as the Plan).

The pharmaceutical and healthcare industries serve as pivotal drivers of Beijing's new quality productive forces. Capitalizing on its world-class business environment and innovation ecosystem, Beijing has attracted leading foreign pharmaceutical companies, such as AstraZeneca, and Eli Lilly and Company, to establish new R&D or/and innovation institutions in 2024. Located along the South 5th Ring Road, the BioPark spans 5.8 square kilometers, with a planned floor area of about 3 million square meters. The park is now home to six specialized centers under China's National Medical Products Administration (NMPA), and R&D hubs from six foreign-invested pharmaceutical giants. Bolstered by its prime location and superb connectivity, the park has vast potential for growth.

The Plan sets forth a two-phase strategy. First, by 2027, the BioPark aims to achieve significant milestones in its planning and construction, with an initial functional layout taking shape. The core facilities of the medical engineering zone will be completed, and a number of innovative projects and medical devices from leading enterprises will be launched. Second, by 2030, the BioPark will have fully developed main functional areas and will serve as a global hub for medical innovation and cooperation, a premier destination for entrepreneurial talented minds, a demonstration zone for AI applications, and a pilot area for policy reforms.

(Source: People's Daily Online)